文献速递浆细胞疾病

既往恶性肿瘤对多发性骨髓瘤患者第二恶性肿瘤及生存的影响:一项基于人群的研究

The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study.
PubMed 文献 · Blood Adv · 2017-11-22

研究基于瑞典癌症登记系统纳入1973年1月1日至2010年12月31日诊断的19791例多发性骨髓瘤患者,评估既往恶性肿瘤对后续恶性肿瘤发生及生存的影响。结果显示,有既往恶性肿瘤者发生后续恶性肿瘤的风险显著升高(HR 1.42,95%CI 1.23-1.65,P<.001),死亡风险亦显著升高(HR 1.21,95%CI 1.115-1.26,P<.001),且有2个及以上既往恶性肿瘤者死亡风险进一步升高(HR 1.34,95%CI 1.19-1.52,P<.001)。

要点

  • 多发性骨髓瘤患者中,有既往恶性肿瘤者后续恶性肿瘤风险显著升高(HR 1.42)。
  • 有既往恶性肿瘤的多发性骨髓瘤患者死亡风险显著升高(HR 1.21)。
  • 有2个及以上既往恶性肿瘤者死亡风险进一步升高至HR 1.34。

核心结论

  • 既往恶性肿瘤增加多发性骨髓瘤患者发生后续恶性肿瘤的风险。
  • 既往恶性肿瘤对多发性骨髓瘤患者生存有负面影响,且超过1个既往恶性肿瘤进一步降低生存。

研究设计与样本

  • 基于瑞典癌症登记系统的基于人群的研究,纳入1973年1月1日至2010年12月31日诊断的多发性骨髓瘤患者共19791例。
  • 采用Cox回归模型计算风险比(HR)及95%置信区间(CI),比较有既往恶性肿瘤与无既往恶性肿瘤的多发性骨髓瘤患者发生后续恶性肿瘤的风险及生存。

主要发现

  • 有既往恶性肿瘤诊断的多发性骨髓瘤患者发生后续恶性肿瘤的风险较无既往恶性肿瘤者显著升高(HR 1.42,95%CI 1.23-1.65,P<.001)。
  • 有既往恶性肿瘤诊断的多发性骨髓瘤患者死亡风险较无既往恶性肿瘤者显著升高(HR 1.21,95%CI 1.115-1.26,P<.001)。
  • 有2个及以上既往恶性肿瘤诊断的多发性骨髓瘤患者死亡风险升高(HR 1.34,95%CI 1.19-1.52,P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the present study, we aimed to evaluate 2 hypotheses. First, we hypothesize that prior malignancy is a proxy for genetic susceptibility that could be a risk factor for subsequent malignancy development in multiple myeloma (MM) patients. Second, we hypothesize that survival after MM is influenced by a prior malignancy. All patients diagnosed with MM from 1 January 1973 to 31 December 2010 were identified from the Swedish Cancer Register. Cox regression model was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) where prior malignancy was compared in MM patients who developed a subsequent malignancy and MM patients who did not. In another Cox regression model, survival was compared in MM patients with and without a prior malignancy diagnosis. A total of 19 791 patients were diagnosed with MM. Patients with a prior malignancy diagnosis had a significantly increased risk of developing a subsequent malignancy compared with MM patients without (HR 1.42, 95% CI 1.23-1.65, P < .001). MM patients with a prior malignancy diagnosis had a significant 1.21-fold increased risk of death (95% CI 1.115-1.26, P < .001) compared with MM patients without. MM patients with 2 or more prior malignancy diagnoses had a 1.34-fold increased risk of death (95% CI 1.19-1.52, P < .001). In this large population-based study, we report that prior malignancy increases the risk of subsequent malignancy development in MM patients. Furthermore, we found that prior malignancy negatively impacts survival and that >1 prior malignancy reduces survival even further.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Jonsdottir G, Lund SH, Björkholm M, et al. The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study. Blood Adv. 2017. PMID: 29296889. doi:10.1182/bloodadvances.2017007930

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。